Network analysis of 23 trials involving 14,293 participants revealed tirzepatide at 10-15mg doses achieves 21.3% total body weight loss, statistically equivalent to sleeve gastrectomy's 21.1% reduction. This dual GLP-1/GIP receptor agonist significantly outperformed semaglutide 2.4mg (12.7% loss) and dramatically exceeded liraglutide 3.0mg (5.1% loss) and orlistat (2.7% loss). The finding represents a watershed moment in obesity pharmacotherapy, offering patients surgical-grade outcomes through weekly injections rather than irreversible gastric surgery. This equivalence challenges the traditional treatment hierarchy where bariatric surgery was considered the gold standard for severe obesity management. However, the analysis reveals important trade-offs: while tirzepatide matches surgical efficacy, semaglutide and orlistat demonstrated superior safety profiles with fewer adverse events. The research strengthens tirzepatide's position as first-line therapy for obesity, particularly for patients seeking maximum weight loss without surgical risks. Yet questions remain about long-term sustainability, cost-effectiveness, and real-world adherence compared to one-time surgical intervention. This comparative effectiveness research provides crucial evidence for clinical decision-making in an era where multiple high-efficacy obesity treatments compete for therapeutic positioning.